{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T20:31:43Z","timestamp":1775161903503,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clinthera.2021.01.021","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T02:28:51Z","timestamp":1613356131000},"page":"500-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions"],"prefix":"10.1016","volume":"43","author":[{"given":"Patrick","family":"Campbell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Symonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"IV","given":"A. Sidney","family":"Barritt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.01.021_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib2","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.01.021_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/aje\/kws448","article-title":"Prevalence of nonalcoholic fatty liver disease in the United States: the third National health and Nutrition examination survey, 1988-1994","volume":"178","author":"Lazo","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review","volume":"56","author":"Thoma","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2021.01.021_bib8","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.22940","article-title":"Independent effects of physical activity in patients with nonalcoholic fatty liver disease","volume":"50","author":"St George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2016.05.026","article-title":"Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver","volume":"65","author":"Sung","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.26393","article-title":"Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial)","volume":"58","author":"Bacchi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2009.01.048","article-title":"Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction","volume":"136","author":"Kirk","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.24242","article-title":"Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects","volume":"53","author":"Haufe","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.clinthera.2021.01.021_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/nu11112601","article-title":"Effects of periodic fasting on fatty liver index\u2014a prospective observational study","volume":"11","author":"Drinda","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.clinthera.2021.01.021_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/hep.24731","article-title":"Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis","volume":"55","author":"Molloy","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)30931-7","article-title":"High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity","volume":"11","author":"Guti\u00e9rrez-Grobe","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European association for the study of the liver, European association for the study of diabetes, European association for the study of obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2008.06.012","article-title":"Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review","volume":"49","author":"Sookoian","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib20","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2021.01.021_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/liv.13747","article-title":"Twenty-five-year trajectories of insulin resistance and pancreatic beta-cell response and diabetes risk in nonalcoholic fatty liver disease","author":"VanWagner","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2021.01.021_bib22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-term follow-up of patients with nonalcoholic fatty liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib23","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/MCG.0b013e31819c392e","article-title":"A\u00a0pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"43","author":"Nelson","year":"2009","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","article-title":"Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial","volume":"46","author":"Lewis","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib26","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.01.021_bib27","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.01.021_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-230X-14-81","article-title":"NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease","volume":"14","author":"Del Ben","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib30","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.01.021_bib31","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2021.01.021_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2021.01.021_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-142-1-200501040-00110","article-title":"Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality","volume":"142","author":"Miller","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2021.01.021_bib34","doi-asserted-by":"crossref","first-page":"c5702","DOI":"10.1136\/bmj.c5702","article-title":"Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials","volume":"341","author":"Schurks","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2021.01.021_bib35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.01.021_bib36","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.01.021_bib37","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2021.01.021_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2021.01.021_bib39","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib40","doi-asserted-by":"crossref","first-page":"109609","DOI":"10.1016\/j.biopha.2019.109609","article-title":"Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease","volume":"121","author":"Xi","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"9972","key":"10.1016\/j.clinthera.2021.01.021_bib41","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.01.021_bib42","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clinthera.2021.01.021_bib43","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/hepr.13425","article-title":"Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis","volume":"49","author":"Sumida","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinthera.2021.01.021_bib44","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clinthera.2021.01.021_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14656566.2018.1543403","article-title":"Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults","volume":"20","author":"Ogawa","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2021.01.021_bib47","first-page":"264","article-title":"Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): review of phase 2 and 3 trials","volume":"6","author":"Connolly","year":"2018","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib48","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib49","first-page":"9","article-title":"New Data on AramcholTM for the treatment of non-alcoholic steatohepatitis: exploring potential for greater efficacy and the effect on glucose metabolism","year":"2019","journal-title":"EMJ Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib50","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.01.021_bib51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13543784.2020.1708899","article-title":"Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2021.01.021_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clinthera.2021.01.021_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.clinthera.2021.01.021_bib55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2021.01.021_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cct.2017.07.015","article-title":"Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: the TARGET-NASH study","volume":"61","author":"Barritt","year":"2017","journal-title":"Contemp Clin Trials"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:52Z","timestamp":1758963292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821000485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0149291821000485"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}